Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

This publication has 24 references indexed in Scilit:

• Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
  The Lancet Rheumatology, 2020
• Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19)
  JAMA, 2020
• Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis
  Nature, 2020
• Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study
  BMJ, 2020
• Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition
  Clinical Immunology, 2017
• The Nature of the P Value
  New England Journal of Medicine, 2016
• Treatment With Anti-C5a Antibody Improves the Outcome of H7N9 Virus Infection in African Green Monkeys
  Clinical Infectious Diseases, 2014
• Acute Respiratory Distress Syndrome
  JAMA, 2012
• A New Equation to Estimate Glomerular Filtration Rate
  Annals of Internal Medicine, 2009
• Deferred consent in emergency intensive care research: what if the patient dies early? Use the data or not?
  Intensive Care Medicine, 2007